Marker Therapeutics, Inc. reported scientific evidence from its Phase 1 APOLLO study demonstrating that lymphodepletion improves the expansion and persistence of Multi-Antigen Recognizing (MAR)-T cells in vivo. This finding was derived using T Cell Receptor (TCR) sequencing as an immunomonitoring strategy.
The data indicated that MT-601 MAR-T cell clones in the drug product expanded and persisted at significantly higher levels in patients who received lymphodepletion compared to those who did not. This suggests that lymphodepletion may positively influence the clinical anti-tumor activity of MT-601 in the ongoing study.
Despite the incorporation of lymphodepletion, MT-601 continued to demonstrate an excellent safety profile, with no dose-limiting toxicities or immune-effector cell associated neurotoxicity syndrome observed. The company also noted a marked increase in patient enrollment, with more patients enrolled and product manufactured in the first five months of 2025 than in the entire year of 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.